Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
???displayArticle.abstract???
Nicotinic acetylcholine receptors (nAChRs) containing α6 and/or α4 subunits modulate the release of dopamine. However, few compounds can effectively discriminate between ligand-binding sites that contain α6 vs. α4 nAChR subunits. Using a chimeric (α6/α4) subunit, we showed that α-conotoxin BuIA binds the extracellular rat α6β2 vs. α4β2 interface with ∼60,000-fold selectivity. Chimeras containing residues from the α6 subunit were inserted into the homologous position of the α4 subunit to identify critical sequence segments. The region between residues 184 and 207 in the α6 subunit accounted for the potency difference. Chimeras within this region followed by point mutations were constructed for further definition. α6 Lys185, Thr187, and Ile188 form a triad of key residues that influence BuIA binding; when these 3 α6 residues were inserted into the α4 subunit, there was an ∼2000-fold increase in toxin potency. We used a crystal structure of BuIA bound to the acetylcholine-binding protein together with the structure of the Torepedo marmorata nAChR to build a homology model of BuIA bound to the interface between α6 and β2 subunits. The results indicate that the triad of α6 residues lies outside the C loop and is distantly located from bound BuIA (>10 Å). This suggests that alterations in potency are not caused by the direct interaction between the triad and BuIA. Instead, alterations in C-loop 3-dimensional structure and/or flexibility may account for differential potency. Thr198 and Tyr205 also contributed to BuIA potency. In addition, Thr198 caused BuIA potency differences between the closely related α6 and α3 subunits. Together, the findings provide insight into differences between the α6 and other α subunits that may be exploited by α-conotoxins to achieve binding selectivity.
Albuquerque,
Mammalian nicotinic acetylcholine receptors: from structure to function.
2009, Pubmed
Albuquerque,
Mammalian nicotinic acetylcholine receptors: from structure to function.
2009,
Pubmed
Arnold,
The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling.
2006,
Pubmed
Azam,
Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors.
2009,
Pubmed
Azam,
Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons.
2002,
Pubmed
Azam,
Amino acid residues that confer high selectivity of the alpha6 nicotinic acetylcholine receptor subunit to alpha-conotoxin MII[S4A,E11A,L15A].
2008,
Pubmed
,
Xenbase
Azam,
Alpha-conotoxin BuIA, a novel peptide from Conus bullatus, distinguishes among neuronal nicotinic acetylcholine receptors.
2005,
Pubmed
,
Xenbase
Bordia,
Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum.
2007,
Pubmed
Brunzell,
Alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors in the nucleus accumbens shell regulate progressive ratio responding maintained by nicotine.
2010,
Pubmed
Buisson,
Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function.
2001,
Pubmed
Cartier,
A new alpha-conotoxin which targets alpha3beta2 nicotinic acetylcholine receptors.
1996,
Pubmed
,
Xenbase
Celie,
Crystal structure of nicotinic acetylcholine receptor homolog AChBP in complex with an alpha-conotoxin PnIA variant.
2005,
Pubmed
,
Xenbase
Celie,
Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures.
2004,
Pubmed
Cheng,
Targeted molecular dynamics study of C-loop closure and channel gating in nicotinic receptors.
2006,
Pubmed
Clark,
The engineering of an orally active conotoxin for the treatment of neuropathic pain.
2010,
Pubmed
Dowell,
Alpha-conotoxin PIA is selective for alpha6 subunit-containing nicotinic acetylcholine receptors.
2003,
Pubmed
,
Xenbase
Evans,
Expression and functional characterisation of a human chimeric nicotinic receptor with alpha6beta4 properties.
2003,
Pubmed
,
Xenbase
Exley,
Distinct contributions of nicotinic acetylcholine receptor subunit alpha4 and subunit alpha6 to the reinforcing effects of nicotine.
2011,
Pubmed
Gotti,
Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation.
2006,
Pubmed
Halai,
Conotoxins: natural product drug leads.
2009,
Pubmed
Han,
Localization of nAChR subunit mRNAs in the brain of Macaca mulatta.
2000,
Pubmed
Hansen,
Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations.
2005,
Pubmed
Humphrey,
VMD: visual molecular dynamics.
1996,
Pubmed
Jackson,
The role of alpha6-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal.
2009,
Pubmed
Kasheverov,
Naturally occurring and synthetic peptides acting on nicotinic acetylcholine receptors.
2009,
Pubmed
Kuryatov,
Human alpha6 AChR subtypes: subunit composition, assembly, and pharmacological responses.
2000,
Pubmed
,
Xenbase
Lai,
Long-term nicotine treatment decreases striatal alpha 6* nicotinic acetylcholine receptor sites and function in mice.
2005,
Pubmed
Le Novère,
The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences.
2002,
Pubmed
Le Novère,
Neuronal nicotinic receptor alpha 6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain.
1996,
Pubmed
Lewis,
Conotoxin venom peptide therapeutics.
2009,
Pubmed
Luo,
alpha-conotoxin AuIB selectively blocks alpha3 beta4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release.
1998,
Pubmed
,
Xenbase
Luo,
Iodo-alpha-conotoxin MI selectively binds the alpha/delta subunit interface of muscle nicotinic acetylcholine receptors.
2004,
Pubmed
,
Xenbase
Luo,
Atypical alpha-conotoxin LtIA from Conus litteratus targets a novel microsite of the alpha3beta2 nicotinic receptor.
2010,
Pubmed
,
Xenbase
Mackerell,
Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations.
2004,
Pubmed
MacKerell,
All-atom empirical potential for molecular modeling and dynamics studies of proteins.
1998,
Pubmed
McCallum,
Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage.
2005,
Pubmed
McIntosh,
Analogs of alpha-conotoxin MII are selective for alpha6-containing nicotinic acetylcholine receptors.
2004,
Pubmed
,
Xenbase
Mordvintsev,
A model for short alpha-neurotoxin bound to nicotinic acetylcholine receptor from Torpedo californica.
2006,
Pubmed
Muttenthaler,
Solving the alpha-conotoxin folding problem: efficient selenium-directed on-resin generation of more potent and stable nicotinic acetylcholine receptor antagonists.
2010,
Pubmed
,
Xenbase
Olivera,
Subtype-selective conopeptides targeted to nicotinic receptors: Concerted discovery and biomedical applications.
2008,
Pubmed
Papke,
Extending the analysis of nicotinic receptor antagonists with the study of alpha6 nicotinic receptor subunit chimeras.
2008,
Pubmed
,
Xenbase
Phillips,
Scalable molecular dynamics with NAMD.
2005,
Pubmed
Pons,
Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration.
2008,
Pubmed
Quik,
Loss of alpha-conotoxinMII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum.
2004,
Pubmed
Quik,
Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or L-DOPA.
2005,
Pubmed
Quik,
Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.
2001,
Pubmed
Quik,
Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy.
2006,
Pubmed
Quik,
Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization.
2000,
Pubmed
Schmidtko,
Ziconotide for treatment of severe chronic pain.
2010,
Pubmed
Shiembob,
Determinants of alpha-conotoxin BuIA selectivity on the nicotinic acetylcholine receptor beta subunit.
2006,
Pubmed
Talley,
Alpha-conotoxin OmIA is a potent ligand for the acetylcholine-binding protein as well as alpha3beta2 and alpha7 nicotinic acetylcholine receptors.
2006,
Pubmed
,
Xenbase
Unwin,
Refined structure of the nicotinic acetylcholine receptor at 4A resolution.
2005,
Pubmed
Yang,
Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology.
2009,
Pubmed